ClinicalTrials.gg
RecruitingNCT05337241Updated Aug 14, 2025

Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT

An interventional study of Saline Enhanced Radiofrequency (SERF) Ablation in Refractory Ventricular Tachycardia, sponsored by Thermedical, Inc.. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Thermedical, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Tachycardia, Ventricular with a site in United States — 34 open to participants now, 40 under way, 2 of them phase 3. Tachycardia, Ventricular · United States.

Planned enrollment
37th of 107
130 · median 60
Started
2025
with 6 others
No phase
68 of 154
18 open now
Primary completion
2027-06
later than 17 of 39 live
Registered
122nd of 154
by date

Among the 154 studies in Tachycardia, Ventricular with a site in United States, this one is the 37th largest by planned enrollment of the 107 interventional ones that give a count, is one of 7 that started in 2025, is one of 68 with no phase, reaches primary completion later than 17 of the 39 other live ones, and was the 122nd registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

34 of the 154 studies in Tachycardia, Ventricular with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Tachycardia, Ventricular with a site in United States, or all of them as a file.
02

Study summary

The Thermedical Ablation System and Durablate catheter is indicated for use in patients with recurrent, sustained, monomorphic ventricular tachycardia (SMVT) refractory to drug therapy and conventional (approved) catheter ablation.

Subjects with recurrent, SMVT refractory to drug therapy and conventional catheter ablation who are not eligible for, or will not likely benefit from repeat endocardial ablation using an approved catheter.

Read the detailed description

This is a staged, non-randomized, open-label, single group, interventional study to be conducted at up to 25 investigational sites to evaluate the safety and efficacy of the Thermedical Ablation System with the Durablate Ablation Catheter (investigational device) in subjects with recurrent, sustained, monomorphic ventricular tachycardia (VT) refractory to drug therapy and conventional catheter ablation.

Subjects will be consented (enrolled) and screened prior to the study ablation procedure. 154 subjects will have a study ablation procedure with the investigational device. Follow-up will occur at 7 days, 30 days, 3 months and 6 months.

The single arm design of the proposed study reflects the nature of the study population. The Thermedical Ablation System was designated as a Breakthrough technology in part because no currently approved device specifically treats this refractory patient population.

03

Conditions studied

  • Refractory Ventricular Tachycardia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has structural heart disease
  2. Subject has recurrent symptomatic sustained (> 30 seconds) monomorphic ventricular tachycardia (MMVT) within 180 days prior to planned study ablation that meets the following criteria:

    1. At least 3 episodes of the MMVT have been treated with ATP and/or shock, OR at least 2 episodes were treated with shock AND
    2. Documentation of the presumed recurrent MMVT was treated with prior catheter ablation AND
    3. Occurred despite treatment with at least one Class III antiarrhythmic after last ablation or treatment with a Class III antiarrhythmic is not tolerated or is AND
    4. VT has recurred despite VT ablation at one of the centers UORU the investigator documents the reason that the subject is unlikely to benefit from a repeat ablation using a conventional, approved catheter.
  3. Subject is at least 18 years old
  4. Subject has an implantable cardioverter-defibrillator (ICD) with a full 6-month (prior to planned study ablation) ICD interrogation history documenting incidences of VT
  5. Subject is able to provide

Exclusion criteria

Exclusion Criteria:

  1. Idiopathic VT (VT occurring in subjects without structural heart disease [including the absence of LGE on MRI, if performed], metabolic abnormalities or long syndrome)
  2. Suspected area of ablation of target clinical VT includes aortic root, aortic cusp or any area outside left ventricle except the ventricular septum
  3. Subject with a prior ablation within 4 weeks of planned study ablation
  4. Subject's VT is not amenable to treatment with the study device at the time of mapping for the study ablation
  5. Only PVCs are induced during mapping for the study ablation
  6. No clinical VT induced during mapping for the study ablation
  7. Planned use of a non-study ablation catheter
  8. Subject has an \< 20% reported on pre-ablation imaging (CT, MRI or echocardiogram within 48 hours of the study procedure)
  9. Subject with evidence of any right- or left-sided (including left atrium, left atrial appendage and left ventricle) intracardiac thrombus OR pericardial effusion (except chronic trivial) reported on required pre-ablation imaging (CT, MRI, or echocardiography) or seen on required procedural intracardiac echocardiography (ICE) prior to study ablation catheter insertion.
  10. Subjects with atrial fibrillation/flutter (paroxysmal, persistent, or permanent) without uninterrupted anticoagulation for at least 3 weeks immediately prior to the date of ablation procedure. (Interruption of anticoagulation in the day(s) just prior to ablation will be left to physician decision based upon subject's risk of stroke, anticoagulation agent, renal status, and bleed/embolic risk status with recommendation to consider bridging for high-risk subjects.
  11. Subjects with Class IV heart failure
  12. Renal dysfunction with \<30 ml/min/1.73mP2
  13. Subject with known coagulopathy or other condition likely to increase risk of periprocedural bleeding
  14. Subject with known coagulopathy or other condition likely to increase risk of a thrombotic event
  15. Subject with a mechanical aortic valve, mechanical mitral valve, or MitraClip
  16. Subject with flail mitral leaflet or severe aortic stenosis
  17. Subject with LAA occlusion device
  18. Subject with a congenital heart defect except patent foramen ovale (PFO)
  19. Subject with suspected of less than 1 year
  20. Subject with myocardial infarction (MI) or unstable angina (UA) within previous 90 days
  21. Subject with cardiac surgery or percutaneous coronary intervention (PCI) within previous 90 days
  22. Subject with known untreated significant ischemic coronary artery disease, acute illness (unrelated to VT or its origin) or active systemic infection.
  23. Subject with left ventricular assist device planned or required for the procedure
  24. Females who are or may potentially be pregnant (must be or have a negative pregnancy test)
  25. Allergy or to the medications/agents used during a standard ablation/EP intervention including heparin and ionic contrast media
  26. Contraindication to cardiac CT
  27. Subject concurrently enrolled in any other drug or device study that the investigator deems would interfere with study results
  28. Subject with a condition (including a chronic illness) or circumstance that the investigator feels puts the subject at an unacceptable risk for participation in the study or may interfere with quality data collection or study results
  29. Subject is not willing or is unable to participate in all study procedures and follow-up requirements

    -

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Single arm treatment

    All subjects meeting inclusion/exclusion criteria and successfully consented will be treated with the study device.

    Device: Saline Enhanced Radiofrequency (SERF) Ablation

Interventions

  • DeviceSaline Enhanced Radiofrequency (SERF) Ablation

    The Durablate intramural needle catheter delivers heated saline to target tissue in the left ventricle to target mid-myocardial and epicardial VT substrates

    Also known as: Intramural Needle Ablation

06

What researchers measure

Primary outcomes

  1. Primary Efficacy (Acute Interim)

    Percentage of target clinical VTs that are non-inducible at end of the study ablation procedure (if PES performed at procedure conclusion)

    Time frame: At end of ablation procedure (ablation procedure occurs on a single day)

  2. Primary Efficacy (Long Term)

    Percentage of subjects who are free from recurrent monomorphic VT

    Time frame: 6 month post ablation

Secondary outcomes

  1. Primary Safety

    Per subject composite of cardiovascular-related and procedure-related major complications through 7 days post-study ablation procedure

    Time frame: 7 days from intervention

07

Study locations

2 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — All data will be de-identified and protected according to HIPAA

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.

Of 40 industry-sponsored interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 52. This study's planned 22 months is below that.

Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2022
First posted
Apr 20, 2022
StartActual
Aug 9, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05337241
Lead sponsor
Thermedical, Inc.
Responsible party
Sponsor
First posted
Apr 20, 2022
Start date
Aug 9, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 14, 2025

Study contacts

Michael Curley, PhD
Contact
mcurley@thermedical.com
617-899-9843
Mary DeVoe
Contact
m.devoe@thermedical.com
Michael Curley, PhD
study director · Thermedical, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion